Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Low‐dose mifepristone (< 25 mg) leads to lower specific side effect ‐ spotting/bleeding after treatment compared with levonorgestrel 1.5 mg (high certainty).
Low‐dose mifepristone (< 25 mg) may leads to lower menses ‐ early compared with levonorgestrel 1.5 mg (low certainty).
Low‐dose mifepristone (< 25 mg) may leads to higher menses ‐ delay compared with levonorgestrel 1.5 mg (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether low‐frequency electroacupuncture changes adverse eventsc compared with physical exercise or no intervention (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
No statistically significant difference in OHRQoL was reported by periodontal-disease prevalence.
No comparative effect estimate was reported; both arms had 0% failure.
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).
Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether laser (low-level laser) at P6 point changes reduction in gagging (assessor-reported) compared with control (sham/dummy laser) (very low certainty).
The review found no eligible studies for this question.
One reported study did not show a clear difference in HIV-related oral lesions for children with CD4+ T-cell counts below 250 cells/mm3.